168 related articles for article (PubMed ID: 35716453)
21. Cancer Therapeutics-related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation.
Peleg Hasson S; Arnold J; Merdler I; Sivan A; Shamai S; Geva R; Merimsky O; Shachar E; Waissengrin B; Moshkovits Y; Arbel Y; Topilsky Y; Rozenbaum Z; Wolf I; Laufer-Perl M
J Immunother; 2021 Jun; 44(5):179-184. PubMed ID: 33950028
[TBL] [Abstract][Full Text] [Related]
22. Monocyte-to-lymphocyte ratio as predictor of cancer therapy-related cardiotoxicity in patients with breast cancer: a pilot cohort study.
Pivatto Júnior F; Santos ÂBS; Englert EF; Mazzutti G; Costa GOM; Saffi MAL; Liedke PER; Fritsch VH; Biolo A
Breast Cancer Res Treat; 2023 Aug; 200(3):355-362. PubMed ID: 37273150
[TBL] [Abstract][Full Text] [Related]
23. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity.
Lambert J; Lamacie M; Thampinathan B; Altaha MA; Esmaeilzadeh M; Nolan M; Fresno CU; Somerset E; Amir E; Marwick TH; Wintersperger BJ; Thavendiranathan P
Heart; 2020 Jun; 106(11):817-823. PubMed ID: 32098808
[TBL] [Abstract][Full Text] [Related]
24. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
[TBL] [Abstract][Full Text] [Related]
25. Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Yu AF; Lin IH; Jorgensen J; Copeland-Halperin R; Feldman S; Ibtida I; Assefa A; Johnson MN; Dang CT; Liu JE; Steingart RM
J Am Heart Assoc; 2023 Oct; 12(19):e029465. PubMed ID: 37750581
[TBL] [Abstract][Full Text] [Related]
26. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
27. Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial.
Negishi T; Thavendiranathan P; Negishi K; Marwick TH;
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1098-1105. PubMed ID: 29909105
[TBL] [Abstract][Full Text] [Related]
28. Risk Stratification for Cardiotoxicity in Breast Cancer Patients: Predicting Early Decline of LVEF After Treatment
Tsiouris KM; Mitsis A; Grigoriadis G; Karanasiou G; Lakkas L; Mauri D; Toli MA; Alexandraki A; Keramida K; Cardinale D; Fotiadis DI
Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-4. PubMed ID: 38083235
[TBL] [Abstract][Full Text] [Related]
29. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
30. Real-life incidence of cardiotoxicity and associated risk factors in sarcoma patients receiving doxorubicin.
Vitfell-Rasmussen J; Krarup-Hansen A; Vaage-Nilsen M; Kümler T; Zerahn B
Acta Oncol; 2022 Jul; 61(7):801-808. PubMed ID: 35695121
[TBL] [Abstract][Full Text] [Related]
31. Pre-Treatment Left Ventricular Ejection Fraction Assessment and Long-Term Cardiovascular Outcomes in Adolescent and Young Adult Lymphoma Survivors.
Farooque A; Osman F; Carroll CB; Ewer S; Lee-Miller C; Tevaarwerk A; Pophali PA
J Adolesc Young Adult Oncol; 2023 Jun; 12(3):331-339. PubMed ID: 36067076
[No Abstract] [Full Text] [Related]
32. Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction.
Saijo Y; Kusunose K; Okushi Y; Yamada H; Toba H; Sata M
Heart; 2020 Nov; 106(22):1752-1758. PubMed ID: 32209616
[TBL] [Abstract][Full Text] [Related]
33. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
34. Assessment of adjuvant trastuzumab-associated cardiac toxicity in korean patients with breast cancer: a single-center analysis.
Cha C; Ahn SG; Lee HM; Lee HW; Lee SA; Jeong J
Oncology; 2013; 85(4):228-34. PubMed ID: 24081024
[TBL] [Abstract][Full Text] [Related]
35. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
36. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines.
Coutinho Cruz M; Moura Branco L; Portugal G; Galrinho A; Timóteo AT; Rio P; Ilhão Moreira R; Mendonça T; Leal A; Gameiro F; Duarte Oliveira S; Luz R; Cruz Ferreira R
Clin Res Cardiol; 2020 Jun; 109(6):673-684. PubMed ID: 31559482
[TBL] [Abstract][Full Text] [Related]
37. Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years.
Jacobse JN; Steggink LC; Sonke GS; Schaapveld M; Hummel YM; Steenbruggen TG; Lefrandt JD; Nuver J; Crijns APG; Aleman BMP; van der Meer P; Gietema JA; van Leeuwen FE
Eur J Heart Fail; 2020 Feb; 22(2):338-346. PubMed ID: 31696625
[TBL] [Abstract][Full Text] [Related]
38. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
[TBL] [Abstract][Full Text] [Related]
39. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman.
Alghafar DA; Younos I; Baimani KA; Al-Salhi D; Al-Riyami A; Rizvi S; Buckley NE
J Oncol Pharm Pract; 2021 Mar; 27(2):312-321. PubMed ID: 32340535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
